Fibrodysplasia ossificans progressiva – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Fibrodysplasia ossificans progressiva – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of Intradermal mRNA COVID-19 Vaccine Bretovameran for Patients with Fibrodysplasia Ossificans Progressiva https://clinicaltrials.eu/trial/study-on-the-safety-of-intradermal-mrna-covid-19-vaccine-bretovameran-for-patients-with-fibrodysplasia-ossificans-progressiva/ Wed, 29 Apr 2026 15:03:57 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-intradermal-mrna-covid-19-vaccine-bretovameran-for-patients-with-fibrodysplasia-ossificans-progressiva/ This clinical trial is focused on studying the safety and effectiveness of a new vaccination method for patients with Fibrodysplasia Ossificans Progressiva (FOP). FOP is a rare condition where the body’s soft tissues gradually turn into bone, leading to mobility issues. The study involves a fractional dose of the Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, which contains the active substance bretovameran. This vaccine is designed to protect against the SARS-CoV-2 virus, which causes COVID-19. The vaccine will be administered as an intradermal injection, meaning it is injected just under the skin, rather than into the muscle.

The purpose of the study is to assess the safety of this vaccination method in FOP patients. Participants will receive a smaller dose than usual, specifically one-fifth of the regular dose. The study will monitor participants for any side effects, such as flare-ups, fever, fatigue, headache, chills, vomiting, diarrhea, muscle pain, and joint pain. Additionally, the study will evaluate the body’s immune response to the vaccine by measuring antibody levels on specific days throughout the study period.

Participants will be observed for any local reactions at the injection site, such as pain, redness, and swelling, as well as any reactions in nearby lymph nodes. The use of medications like corticosteroids, antipyretics, and painkillers will also be tracked. The study aims to provide valuable information on how well the vaccine works and how safe it is for people with FOP, contributing to better healthcare options for those affected by this rare condition.

]]> Study on the Safety and Effects of Saracatinib for Patients with Fibrodysplasia Ossificans Progressiva (FOP) https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-saracatinib-for-patients-with-fibrodysplasia-ossificans-progressiva-fop/ Wed, 29 Apr 2026 15:02:53 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-saracatinib-for-patients-with-fibrodysplasia-ossificans-progressiva-fop/ This clinical trial is focused on studying a rare condition called Fibrodysplasia Ossificans Progressiva (FOP). FOP is a disorder where soft tissues, like muscles and tendons, gradually turn into bone, leading to restricted movement. The trial is testing a research medication known as AZD0530, also called Saracatinib, which is taken as a film-coated tablet. The purpose of the study is to evaluate the safety and effects of Saracatinib on abnormal bone formation in patients with FOP.

Participants in the study will receive either Saracatinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of 18 months, during which participants will be monitored for any new bone growth and any side effects that may occur. The study will include regular check-ups and imaging tests, such as PET and CT scans, to assess the development of new bone lesions and the overall impact of the treatment.

The trial aims to provide valuable information on how Saracatinib affects the progression of FOP and its potential to prevent new bone formation. By participating in this study, researchers hope to gain insights that could lead to better treatment options for individuals living with this challenging condition.

]]> Study on the Effectiveness of INCB000928 for Patients with Fibrodysplasia Ossificans Progressiva https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-incb000928-for-patients-with-fibrodysplasia-ossificans-progressiva/ Wed, 29 Apr 2026 14:59:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-incb000928-for-patients-with-fibrodysplasia-ossificans-progressiva/ This clinical trial is focused on studying a rare disease called Fibrodysplasia Ossificans Progressiva (FOP). FOP is a condition where the body’s soft tissues, like muscles and tendons, gradually turn into bone, leading to stiffness and movement difficulties. The study is testing a new treatment called INCB000928, which is taken as a film-coated tablet. This medication is an ALK2 inhibitor, which means it is designed to block a specific protein that may play a role in the abnormal bone growth seen in FOP.

The purpose of the study is to evaluate how effective and safe INCB000928 is in preventing new bone growth in people with FOP. Participants in the study will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study is conducted in a double-blind manner, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication or placebo for a period of time and will have regular check-ups to monitor their health and any changes in their condition. The study will assess the total volume of new bone growth and the number of new flare-ups, which are episodes of swelling and pain. The study aims to provide valuable information on whether INCB000928 can help manage FOP and improve the quality of life for those affected by this challenging condition.

]]> Study on the Safety and Effectiveness of Garetosmab for Adults with Fibrodysplasia Ossificans Progressiva https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-garetosmab-for-adults-with-fibrodysplasia-ossificans-progressiva/ Wed, 29 Apr 2026 14:29:27 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-garetosmab-for-adults-with-fibrodysplasia-ossificans-progressiva/ This clinical trial is focused on studying a rare disease called Fibrodysplasia Ossificans Progressiva (FOP). FOP is a condition where soft tissues in the body, like muscles and tendons, gradually turn into bone, leading to stiffness and movement difficulties. The study is testing a treatment called Garetosmab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific substances in the body. In this case, Garetosmab is aimed at reducing the formation of new bone in soft tissues.

The purpose of the study is to evaluate the safety and effectiveness of Garetosmab compared to a placebo. Participants will receive the treatment through an intravenous (IV) infusion, which means the medication is given directly into a vein. The study will last for about 56 weeks, during which participants will be monitored for any new bone growth and any side effects they might experience. The study will use low-dose computed tomography (CT) scans to check for new bone formation.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their condition. The study aims to provide valuable information on whether Garetosmab can help manage FOP by preventing new bone growth in soft tissues, ultimately improving the quality of life for those affected by this challenging condition.

]]>